These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31420411)

  • 1. Secondary cytoreductive surgery in recurrent uterine leiomyosarcoma: a multi-institutional study.
    Bizzarri N; Ghirardi V; Di Fiore GLM; De Iaco P; Gadducci A; Casarin J; Perrone AM; Pasciuto T; Scambia G; Fagotti A
    Int J Gynecol Cancer; 2019 Sep; 29(7):1134-1140. PubMed ID: 31420411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma.
    Giuntoli RL; Garrett-Mayer E; Bristow RE; Gostout BS
    Gynecol Oncol; 2007 Jul; 106(1):82-8. PubMed ID: 17434579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer.
    Felsinger M; Minar L; Weinberger V; Rovny I; Zlamal F; Bienertova-Vasku J
    Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():154-160. PubMed ID: 29957400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secondary surgical resection for patients with recurrent uterine leiomyosarcoma.
    Cybulska P; Sioulas V; Orfanelli T; Zivanovic O; Mueller JJ; Broach VA; Long Roche KC; Sonoda Y; Hensley ML; O'Cearbhaill RE; Chi DS; Alektiar KM; Abu-Rustum NR; Leitao MM
    Gynecol Oncol; 2019 Aug; 154(2):333-337. PubMed ID: 31200927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Hyperthermic Intraperitoneal Chemotherapy and Cytoreductive Surgery in the Treatment of Recurrent Uterine Sarcoma.
    Díaz-Montes TP; El-Sharkawy F; Lynam S; Harper A; Sittig M; MacDonald R; Gushchin V; Sardi A
    Int J Gynecol Cancer; 2018 Jul; 28(6):1130-1137. PubMed ID: 29975291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical and oncologic outcomes of hyperthermic intraperitoneal chemotherapy for uterine leiomyosarcoma: A systematic review of literature.
    Matsuzaki S; Matsuzaki S; Chang EJ; Yasukawa M; Roman LD; Matsuo K
    Gynecol Oncol; 2021 Apr; 161(1):70-77. PubMed ID: 33419612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma.
    Leitao MM; Brennan MF; Hensley M; Sonoda Y; Hummer A; Bhaskaran D; Venkatraman E; Alektiar K; Barakat RR
    Gynecol Oncol; 2002 Dec; 87(3):287-94. PubMed ID: 12468327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncological outcomes of unexpected uterine leiomyosarcoma: A single-center retrospective analysis of 5528 consecutive hysterectomies.
    Casarin J; Ghezzi F; Lembo A; Artuso V; Schivardi G; Galati EF; Ambrosoli AL; Bogani G; Multinu F; Cromi A
    J Surg Oncol; 2024 Mar; 129(3):517-522. PubMed ID: 37974522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma.
    Iasonos A; Keung EZ; Zivanovic O; Mancari R; Peiretti M; Nucci M; George S; Colombo N; Carinelli S; Hensley ML; Raut CP
    Cancer; 2013 May; 119(10):1816-22. PubMed ID: 23456762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma.
    George S; Barysauskas C; Serrano C; Oduyebo T; Rauh-Hain JA; Del Carmen MG; Demetri GD; Muto MG
    Cancer; 2014 Oct; 120(20):3154-8. PubMed ID: 24923260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of re-exploration in patients with inadvertently morcellated uterine sarcoma.
    Oduyebo T; Rauh-Hain AJ; Meserve EE; Seidman MA; Hinchcliff E; George S; Quade B; Nucci MR; Del Carmen MG; Muto MG
    Gynecol Oncol; 2014 Feb; 132(2):360-5. PubMed ID: 24296345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of women with recurrent or persistent uterine leiomyosarcoma.
    Rauh-Hain JA; Hinchcliff EM; Oduyebo T; Worley MJ; Andrade CA; Schorge JO; George S; Muto MG; del Carmen MG
    Int J Gynecol Cancer; 2014 Oct; 24(8):1434-40. PubMed ID: 25248114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
    Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
    Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoreductive Surgery and HIPEC as a Treatment Option for Laparoscopic Resection of Uterine Leiomyosarcoma with Morcellation: Early Results.
    Sugarbaker P; Ihemelandu C; Bijelic L
    Ann Surg Oncol; 2016 May; 23(5):1501-7. PubMed ID: 26545375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis.
    Leitao MM; Zivanovic O; Chi DS; Hensley ML; O'Cearbhaill R; Soslow RA; Barakat RR
    Gynecol Oncol; 2012 May; 125(2):409-13. PubMed ID: 22366592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of morcellation on survival outcomes of patients with unexpected uterine leiomyosarcoma: a systematic review and meta-analysis.
    Bogani G; Cliby WA; Aletti GD
    Gynecol Oncol; 2015 Apr; 137(1):167-72. PubMed ID: 25462199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand.
    Potikul C; Tangjitgamol S; Khunnarong J; Srijaipracharoen S; Thavaramara T; Pataradool K
    Asian Pac J Cancer Prev; 2016; 17(4):1759-67. PubMed ID: 27221849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors and survival outcomes of women with uterine leiomyosarcoma: A Turkish Uterine Sarcoma Group Study-003.
    Ayhan A; Gungorduk K; Khatib G; Fırat Cüylan Z; Boran N; Gökçü M; Çelik H; Özgül N; Akbayir Ö; Şimşek T; Bakay A; Faruk Köse M; Tunç M; Küçükgöz Güleç Ü; Koç S; Kuşçu E; Vardar MA; Akilli H; Taskiran C; Mutlu Meydanlı M
    Curr Probl Cancer; 2021 Oct; 45(5):100712. PubMed ID: 33685725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical status and prognostic factors in Japanese patients with uterine leiomyosarcoma.
    Takehara K; Yamashita N; Watanabe R; Teramoto N; Tsuda H; Motohashi T; Harano K; Nakanishi T; Tokunaga H; Susumu N; Ueda Y; Yokoyama Y; Saito T
    Gynecol Oncol; 2020 Apr; 157(1):115-120. PubMed ID: 31983515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of tumor fragmentation in patients with stage I uterine leiomyosarcoma on patterns of recurrence and oncologic outcome.
    Pedra Nobre S; Hensley ML; So M; Zhou QC; Iasonos A; Leitao MM; Ducie J; Chiang S; Mueller JJ; Abu-Rustum NR; Zivanovic O
    Gynecol Oncol; 2021 Jan; 160(1):99-105. PubMed ID: 33158511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.